Evolution of the Serbian pharmaceutical market alongside socioeconomic transition

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 3, 2015, Pages 521-530

  Jakovljevic, Mihajlo B ^a   Djordjevic, Natasa ^a   Jurisevic, Milena ^a   Jankovic, Slobodan ^a,b  

^a University of Kragujevac Medical Faculty   (Serbia)

^b CLINICAL CENTER KRAGUJEVAC   (Serbia)

Author keywords

expenditure; pharmaceutical market; reimbursement; Serbia; socioeconomic transition; transformation; trend; Western Balkans

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; DRUG;

BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG MARKETING; EVIDENCE BASED MEDICINE; FINANCIAL DEFICIT; GOVERNMENT; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INCOME; PRESCRIPTION; PUBLIC HEALTH; REIMBURSEMENT; REVIEW; SERBIA; SOCIAL SUPPORT; SOCIOECONOMICS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; SUPPLY AND DISTRIBUTION; TRENDS;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH CARE REFORM; HEALTH EXPENDITURES; HUMANS; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS; SERBIA; SOCIOECONOMIC FACTORS;

EID: 84929259314     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1003044     Document Type: Review

References (44)

1. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21(2):89-103
2. Huys I, Simoens S. European drug shortages: a call for action!. Int J Pharm Pract 2013;21(1):1-2
3. Karanikolos M, Mladovsky P, Cylus J, et al. Financial crisis, austerity, and health in Europe. Lancet 2013;381(9874):1323-31
4. Mossialos E, Mrazek M, Walley T. Regulating Pharmaceuticals in Europe: Striving for efficiency, equity and quality. Open University Press; London: 2004
5. Tomanovi S, Ignjatovic S. The transition of young people in a transitional society: the case of Serbia. J Youth Stud 2006;9(3): 269-85
6. Mossialos E, Dixon A, Figueras J, Kutzin J. Funding health care: options for Europe. Open University Press; Buckingham-Philadelphia: 2002
7. Borowitz M, Atun R. The unfinished journey from Semashko to Bismarck: health reform in Central Asia from 1991 to 2006. Centr Asian Surv 2006;25(4):419-40
8. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013;14(2):153-9
9. Pantovic B. Recognition as welfare in globalization. 2011;LXIX(1):155-64
10. Goldstein E, Preker AS, Adeyi O, Chellaraj G. Trends in health status, services, and finance: the transition in Central and Eastern Europe (No. 341). World Bank Publications, Washington, D. C;1996
11. Bandelj N. The global economy as instituted process: the case of Central and Eastern Europe. Am Sociol Rev 2009;74(1): 128-49
12. Criterion for price fromation fro drug used in human medicine. Available from: www.podaci.net/-gSRB/f/formiranje/ formiranje-cena/formiranje-cena.html [Last accessed 5 June 2014]
13. Medicines and Medicals Devices Agency of Serbia. Preparation of Professional Publications of the Agency. Belgrade, 2014. Available from: www.alims.gov.rs/eng/about-agency/publication/ [Last accessed 5 June 2014]
14. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available from: www.whocc.no/atc ddd-index/?code=L01XC [Last accessed 5 June 2014]
15. Jakovljevic MB, Djordjevic V, Markovic V, et al. Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country. Chin J Integr Med 2013; 19(9):650-5
16. Cupara E, Djordjevic N, Jakovljevic M. Current legal status and research on complementary and alternative medicine in Serbia. J Altern Med Res 2013;5(3):195-8
17. National Health Insurance Fund. Available from: www.eng.rfzo.rs/ [Last accessed 5 June 2014]
18. National Assembly of the Republic of Serbia. Available from: www.parlament.gov. rs/acts/adopted-laws/adopted-laws.628.html [Last accessed 5 June 2014]
19. Act on content and scope of rights on healthcare financed from obligatory health insurance, including reimbursement rates for year 2014. Official Gazette of Republic of Serbia, No. 3/2014.
20. Act on content and scope of rights on healthcare financed from obligatory health insurance, including reimbursement rates for year 2009. Official Gazette of Republic of Serbia, Nos. 7/2009 and 82/2009
21. Arsenijevic J, Pavlova M, Groot W. Out-of-pocket payments for public healthcare services by selected exempted groups in Serbia during the period of post-war healthcare reforms. Int J Health Plann Manage 2013;29(4):373-98
22. Arsenijevic J, Pavlova M, Groot W. Measuring the catastrophic and impoverishing effect of household health care spending in Serbia. Soc Sci Med 2013;78:17-25
23. Radovanovic A, Dagovic A, Jakovljevic M. Economics of cancer related medical care: estimates worldwide and available domestic evidence. Arch Oncol 2011;19(3-4):59-63
24. Lazic Z, Gajovic O, Tanaskovic I, et al. GOLD stage impact on COPD direct medical costs in elderly. Health Behav & Pub Health 2012;2(3):1-7
25. Jakovljevic M, Lazic Z, Verhaeghe N, et al. Direct medical costs of COPD diagnosis and treatment, Eastern vs. Western European country: examples of Serbia and Belgium. Farmeconomia Health Econimics and Therapeutic Pathways 2013;14(4):161-8
26. Biorac N, Jakovljevic M, Stefanovic D, et al. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. Vojnosanit Pregl 2009;66(4):271-6
27. Dragan Ilic. Institute of public health of Serbia "Dr Milan Jovanovic Batut". Health statistical yearbook of republic of Serbia 2012. Beograd, 2012. Available from: www. batut.org.rs/download/publikacije/pub2012. pdf [Last accessed 5 June 2014]
28. Kovacevic A, Dragojevic-Simic V, Rancic N, et al. End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit Pregl 2015;72(4):In press
29. Jakovljevic MB. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia Health Economics and Therapeutic Pathways 2014; 15(1):27-32
30. State and structure of public debt-June 2014. Ministry of finance of Republic of Serbia-Center for public debt. Available from: www.javnidug.gov.rs/upload/Stanje% 20i%20struktura/Stanje%20i%20struktura% 20-%20SRB%20LATINICA.pdf [Last accessed 7 June 2014]
31. Quality of care parameters 2008-2012. Clinical Center Kragujevac. Available from: www.kc-kg.rs/kvalitet/kvalitet-rada [Last accessed 7 June 2014]
32. Delnoij D, Van Merode G, Paulus A, Groenewegen P. Does general practitioner gatekeeping curb health care expenditure? J Health Serv Res Policy 2000;5(1):22-6
33. Forrest CB. Primary care in the United States: primary care gatekeeping and referrals: effective filter or failed experiment? BMJ 2003;326(7391):692-5
34. Rankovic A, Rancic N, Jovanovic M, et al. Impact of imaging diagnostics on the budget-are we spending too much? Vojnosanit Pregl 2013;70(7):709-11
35. Jakovljevic M, Rankovic A, Rančic N, et al. Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe-A Retrospective Analysis from Serbia. Value in Health Regional Issues 2013;2(2):218-25
36. Jakovljevic M. Recent developments among world's leading generic markets. Medicinski Casopis 2014;48:3
37. Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan-key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res 2014;14(2):181-94
38. Yamada T, Chen CC, Yamada T, et al. Pharmaceutical price control policy, pharmaceutical innovation, and health durability. Open Pharmacoeconomics Health Econ J 2010;2:34-46
39. Nautre B, Georgieva M. Bulgarian hospital reform and the new public management model. A change of role of state or a change of mind? Scr Sci Med 2013;45(4):20-30
40. Nemec J, Cankar SS, Kostadinova T, et al. Financing Health Care: what Can we Learn from CEE Experience? Administrative Culture 2013;14(2):212-37
41. Czachowski S, Pawlikowska T. 'These reforms killed me': doctors' perceptions of family medicine during the transition from communism to capitalism. Fam Pract 2011; 28(4):437-43
42. Gotsadze G, Chikovani I, Goguadze K, et al. Reforming sanitary-epidemiological service in Central and Eastern Europe and the former Soviet Union: an exploratory study. BMC Public Health 2010;10:440
43. Bjegovic V, Vukovic D, Terzic Z, et al. Strategic orientation of public health in transition: an overview of South Eastern Europe. J Public Health Policy 2007;28(1): 94-101
44. Ider BE, Adams J, Morton A, et al. Infection control systems in transition: the challenges for post-Soviet Bloc countries. J Hosp Infect 2012;80(4):277-87